^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | PD-L1-targeted CAR-T immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
889 / 4 - The efficacy and safety of PD-L1-specific CAR-T in advanced gastric cancer
Published date:
03/15/2023
Excerpt:
The effector CAR-T, named Vax-CAR-T, specifically recognized the PD-L1-expressing AGC cell line, SNU638, and exhibited rapid and robust cytotoxic activity in vitro….Vax-CAR-T cells significantly suppressed tumor growth in both bigger (>95mm3) and smaller (≤50mm3) AGC xenograft NSG mouse models....We believe that a new autologous CAR-T targeting PD-L1 could be a promising new tool for removing heterogeneous solid tumors in TME, which would be a significant step forward in improving current conventional and immunotherapeutic strategies.
